RT Journal Article
SR Electronic
T1 Myelin pathology in ataxia-telangiectasia is the cell-intrinsic consequence of ATM deficiency in the oligodendrocytes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.20245217
DO 10.1101/2021.01.22.20245217
A1 Tse, Kai-Hei
A1 Cheng, Aifang
A1 Yeung, Sunny Hoi-Sang
A1 Cheng, Gerald Wai-Yeung
A1 Wang, Qingyang
A1 Zhu, Beika
A1 Cui, Yong
A1 Jiang, Liwen
A1 Kofler, Julia
A1 Herrup, Karl
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.22.20245217.abstract
AB Ataxia-telangiectasia (A-T) is a rare genetic disease caused by mutations in the gene encoding the ATM (Ataxia-telangiectasia mutated) protein. Although neuronal degeneration in the cerebellum remains the most prominent sign in A-T, neuroimaging studies reveal myelin abnormalities as early comorbidities. We hypothesize that these myelin defects are the direct consequence of ATM deficiencies in the oligodendrocytes (OL) lineage. We examined samples from ten A-T brains in which the ATM mutations had been mapped by targeted genomic sequencing as well as samples from Atm-/- mice. In healthy human and wild type mouse cerebellum we confirmed the presence of ATM in white matter OLs. In A-T but not age-matched controls, a significant reduction in OL density was coupled with a massive astrogliosis. We found that the extent of this OL pathology was particularly strong in cases with frameshifts or premature termination ATM mutations. Similar pathologies were also found in Atm-/- mice in an age- and gene dose-dependent fashion. In vitro, DNA damage induced by etoposide-induced DSBs or blockade of ATM activity with KU-60019 differentially jeopardized cell cycle control in OL progenitors and mature OLs. Turning to structural analysis in silico, we identified likely interactions between ATM and myelin basic protein as well as myelin regulatory factor and confirm this by immunoprecipitation. These novel OL-specific functions of the ATM protein affect all stages of the OL lineage. They thus provide a cell biological basis for a direct role for ATM in central nervous system myelination and illustrate how the myelin pathology found in A-T is at least in part independent of neuronal degeneration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe present work was generously supported by Health and Medical Research Fund (HMRF06173836 and HMRF04151436) of the Food and Health Bureau, Hong Kong Special Administrative Region, as well as National Institute of Neurological Disorders and Stroke (NINDS) R01NS071022-01. We acknowledge the kind support from the staff at NeuroBioBank of National Institutes of Health (NIH). All frozen human tissue in this study was obtained from the NIH NeuroBioBank at the University of Maryland, Baltimore, MD, and the PPFE tissues from Neuropathology Core, University of Pittsburgh Alzheimer's Disease Research Center, United States. Dr Kofler and Alzheimer's Disease Research Center at the University of Pittsburgh are supported by NIA P30 AG066468 and NIA P50 AG005133. Dr Jiang and the TEM work are supported by AoE/M-05/12.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All experiments on post-mortem human brain tissues were approved by the Committee of Research Practices at The Hong Kong University of Science and Technology (HKUST) as well as Human Subjects Ethics Application Review board at The Hong Kong Polytechnic University (PolyU) All experimnets on animal models were approved by the Animal Ethics Committee, of the Committee on Research Practices of HKUST and Animal Subjects Ethics Sub-Committee of PolyU. All procedures were also conducted with a license from the Department of Health, Government of Hong Kong.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.